oxytocin
Oxytocin causes uterine contractions and is used in obstetric care to induce labor and control bleeding after delivery. Nasal sprays have also been studied for social behavior, anxiety and sexual function, with inconsistent results. Large autism and trust studies found no meaningful benefit on their main outcomes.
Endogenous cyclic nonapeptide and oxytocin-receptor agonist
- Current Pitocin is a 10 units/mL synthetic oxytocin injection.
- The label excludes elective induction and requires hospital IV monitoring for labor induction or stimulation.
- The former US Syntocinon nasal approval was withdrawn in 1997 after commercial discontinuation.
- A 290-person youth autism trial was null on its primary social outcome.
- A 2026 registered trust replication and 532-person pooled analysis found no meaningful trust-game effect.
- Controlled sexual-function findings are mixed and do not establish a reliable libido or orgasm treatment.
How do injectable and nasal oxytocin differ?
Injectable oxytocin is an approved obstetric medicine. Nasal formulations have been studied for social behavior, psychiatric symptoms and sexual function, but the cited FDA records contain no current U.S. approval for those uses.
| Use | Product and setting | Outcome measured | What the evidence says |
|---|---|---|---|
| Labor induction or augmentation | Pitocin IV infusion in a hospital | Uterine response plus maternal and fetal safety | FDA-labeled for medically indicated use with continuous monitoring |
| Postpartum bleeding control | Pitocin IV infusion or indicated IM use in obstetric care | Sustained uterine contraction and bleeding control | FDA-labeled acute use |
| Behavioral or psychiatric research | Study-specific intranasal spray | Diagnosis-specific symptom scale or laboratory task | No current US approved nasal product or behavioral indication identified |
| Compounded nasal use | Pharmacy-specific formulation and device | The prescribed target plus product quality | Not FDA-approved; trial results do not prove equivalence to that preparation |
Units, exposure, and device are not interchangeable across rows.
Pitocin label · indications, route, monitoring, harms
Current US prescribing information
DailyMed, US National Library of Medicine, revised March 2026
The label identifies Pitocin as synthetic oxytocin 10 units/mL for intravenous infusion or intramuscular injection. It covers medically indicated initiation or improvement of uterine contractions, selected abortion management, third-stage uterine contraction, and control of postpartum bleeding or hemorrhage. It says the drug is not indicated for elective induction. Induction or stimulation requires intravenous infusion in a hospital with continuous observation and fetal monitoring.
- The label reports a plasma half-life of about 1 to 6 minutes.
- Excess exposure can cause uterine hypertonicity, tetanic contraction, rupture, fetal hypoxia, and death.
- Its antidiuretic action can cause severe water intoxication with convulsions or coma during prolonged high-dose infusion.
- Participants / model
- Pregnant and postpartum patients in monitored obstetric care
- Treatment
- Oxytocin injection, 10 units/mL; intravenous infusion for induction or stimulation and intravenous infusion or intramuscular injection in specified postpartum use
- Follow-up
- Acute, clinician-controlled obstetric administration
- Study design
- FDA-regulated product label
A product label defines approved use and warnings. It does not validate intranasal behavioral or sexual uses.
Read the original sourceOrange Book 2026 · nasal product discontinued
Current FDA drug-product directory
US Food and Drug Administration, Approved Drug Products with Therapeutic Equivalence Evaluations, 46th edition, 2026
The 2026 discontinued-products list includes Syntocinon oxytocin nasal solution, 40 USP units/mL, NDA 012285. The same list separately identifies discontinued injectable oxytocin products. It does not show a currently marketed US nasal oxytocin approval.
- Participants / model
- US approved-drug product records
- Treatment
- Syntocinon nasal solution 40 USP units/mL
- Follow-up
- Directory status as published in 2026
- Study design
- FDA regulatory directory
Discontinued listing describes market status. The reason for withdrawal comes from the 1997 Federal Register notice.
Read the original sourceFDA compounding Q&A · what approval does not cover
Current FDA regulatory guidance page
US Food and Drug Administration, updated 2026
FDA states that compounded drugs are not FDA-approved and that the agency does not verify their safety, effectiveness, or quality before marketing. Compounding may meet an individual need, but facility, formulation, concentration, and device still matter.
- Participants / model
- US compounded human drugs
- Treatment
- General compounding framework
- Study design
- FDA public guidance
This source does not decide whether a particular prescription or preparation satisfies every applicable compounding rule.
Read the original sourceWhat is oxytocin?
Oxytocin is a cyclic nine-amino-acid hormone. Its receptor raises calcium inside uterine muscle cells, causing contractions. Nasal studies examine effects on brain activity and behavior, but clinical trials have produced inconsistent results.
- Identity: CYIQNCPLG, with a disulfide bridge between cysteines 1 and 6 and an amidated terminus.
- Peripheral action: OXTR activation in the pregnant uterus increases intracellular calcium and contraction. Receptor density and uterine sensitivity rise around labor.
- Central research: nasal studies probe social attention, threat processing, learning, and other circuits. A neural or laboratory-task effect is not automatically a useful treatment effect.
FDA SRS · molecular identity
Official substance identity record
US Food and Drug Administration, Substance Registration System
FDA records oxytocin under UNII 1JQS135EYN as the cyclic nine-residue peptide CYIQNCPLG with a disulfide link between cysteines 1 and 6 and an amidated glycine terminus.
- Participants / model
- Not applicable
- Treatment
- Substance identity only
- Follow-up
- Not applicable
- Study design
- Regulatory molecular registry
Identity does not establish a clinical effect for any route or indication.
Read the original sourcePitocin label · indications, route, monitoring, harms
Current US prescribing information
DailyMed, US National Library of Medicine, revised March 2026
The label identifies Pitocin as synthetic oxytocin 10 units/mL for intravenous infusion or intramuscular injection. It covers medically indicated initiation or improvement of uterine contractions, selected abortion management, third-stage uterine contraction, and control of postpartum bleeding or hemorrhage. It says the drug is not indicated for elective induction. Induction or stimulation requires intravenous infusion in a hospital with continuous observation and fetal monitoring.
- The label reports a plasma half-life of about 1 to 6 minutes.
- Excess exposure can cause uterine hypertonicity, tetanic contraction, rupture, fetal hypoxia, and death.
- Its antidiuretic action can cause severe water intoxication with convulsions or coma during prolonged high-dose infusion.
- Participants / model
- Pregnant and postpartum patients in monitored obstetric care
- Treatment
- Oxytocin injection, 10 units/mL; intravenous infusion for induction or stimulation and intravenous infusion or intramuscular injection in specified postpartum use
- Follow-up
- Acute, clinician-controlled obstetric administration
- Study design
- FDA-regulated product label
A product label defines approved use and warnings. It does not validate intranasal behavioral or sexual uses.
Read the original sourceMethods review · route, device, dose, timing, replication
Translational methods review
Quintana DS et al. Molecular Psychiatry. 2021
The review finds converging human and animal evidence that intranasal delivery can produce functionally relevant central effects, while emphasizing unresolved route mechanisms and the need to account for device, dose, timing, preregistration, statistical power, reproducibility, and sex. It does not support treating one CSF timing estimate as a universal nasal half-life.
- Participants / model
- Human and animal intranasal oxytocin literature
- Treatment
- Intranasal oxytocin across formulations, devices, and experimental protocols
- Follow-up
- Literature through 2020
- Study design
- Narrative translational methods review
A methods review supports interpretation of route and measurement. It is not proof of efficacy for any diagnosis.
Read the original sourceWhat is Pitocin approved for?
The Pitocin label covers the obstetric uses listed below. It excludes elective labor induction without a medical indication and does not approve social, psychiatric or sexual uses.
- Initiation of labor when maternal or fetal circumstances make induction medically indicated.
- Stimulation or reinforcement of labor in selected uterine inertia.
- Adjunctive management of incomplete or inevitable abortion.
- Uterine contraction during the third stage of labor and control of postpartum bleeding or hemorrhage.
Pitocin label · indications, route, monitoring, harms
Current US prescribing information
DailyMed, US National Library of Medicine, revised March 2026
The label identifies Pitocin as synthetic oxytocin 10 units/mL for intravenous infusion or intramuscular injection. It covers medically indicated initiation or improvement of uterine contractions, selected abortion management, third-stage uterine contraction, and control of postpartum bleeding or hemorrhage. It says the drug is not indicated for elective induction. Induction or stimulation requires intravenous infusion in a hospital with continuous observation and fetal monitoring.
- The label reports a plasma half-life of about 1 to 6 minutes.
- Excess exposure can cause uterine hypertonicity, tetanic contraction, rupture, fetal hypoxia, and death.
- Its antidiuretic action can cause severe water intoxication with convulsions or coma during prolonged high-dose infusion.
- Participants / model
- Pregnant and postpartum patients in monitored obstetric care
- Treatment
- Oxytocin injection, 10 units/mL; intravenous infusion for induction or stimulation and intravenous infusion or intramuscular injection in specified postpartum use
- Follow-up
- Acute, clinician-controlled obstetric administration
- Study design
- FDA-regulated product label
A product label defines approved use and warnings. It does not validate intranasal behavioral or sexual uses.
Read the original sourceWhy is labor use a monitored hospital intervention?
The desired uterine effect can overshoot. The label requires IV infusion with continuous trained observation and electronic fetal monitoring for induction or stimulation because excessive frequency, strength, or duration of contractions can compromise both patient and fetus.
- Uterine and delivery harms: hypertonicity, spasm, tetanic contraction, rupture, cervical or vaginal laceration, and postpartum hemorrhage.
- Fetal and neonatal harms: altered fetal heart rate, hypoxia, hypercapnia, brain injury, perinatal hepatic necrosis, or death can follow uteroplacental hypoperfusion.
- Fluid risk: oxytocin has intrinsic antidiuretic activity. Prolonged high exposure with fluid intake can cause water intoxication, seizures, coma, or death.
- Interaction context: the label reports severe hypertension when oxytocin followed prophylactic vasoconstrictor use around caudal-block anesthesia; anesthetic and fluid plans therefore belong to the obstetric team.
Major contraindications include situations where vaginal delivery is contraindicated, major cephalopelvic disproportion, an undeliverable fetal position, fetal distress when delivery is not imminent, hyperactive or hypertonic uterus, and failed adequate uterine response.
Pitocin label · indications, route, monitoring, harms
Current US prescribing information
DailyMed, US National Library of Medicine, revised March 2026
The label identifies Pitocin as synthetic oxytocin 10 units/mL for intravenous infusion or intramuscular injection. It covers medically indicated initiation or improvement of uterine contractions, selected abortion management, third-stage uterine contraction, and control of postpartum bleeding or hemorrhage. It says the drug is not indicated for elective induction. Induction or stimulation requires intravenous infusion in a hospital with continuous observation and fetal monitoring.
- The label reports a plasma half-life of about 1 to 6 minutes.
- Excess exposure can cause uterine hypertonicity, tetanic contraction, rupture, fetal hypoxia, and death.
- Its antidiuretic action can cause severe water intoxication with convulsions or coma during prolonged high-dose infusion.
- Participants / model
- Pregnant and postpartum patients in monitored obstetric care
- Treatment
- Oxytocin injection, 10 units/mL; intravenous infusion for induction or stimulation and intravenous infusion or intramuscular injection in specified postpartum use
- Follow-up
- Acute, clinician-controlled obstetric administration
- Study design
- FDA-regulated product label
A product label defines approved use and warnings. It does not validate intranasal behavioral or sexual uses.
Read the original sourceDoes intranasal oxytocin improve autism symptoms?
The largest youth trial found no benefit on its primary social outcome. Smaller studies reported signals, including a Chinese pilot that paired oxytocin with structured positive interaction, but those results have not established a broadly effective autism treatment.
| Study | Population and product | Primary result | What it can support |
|---|---|---|---|
| SOARS-B, US | 290 ages 3 to 17; daily flexible-dose nasal oxytocin | ABC social-withdrawal difference -0.2, 95% CI -1.5 to 1.0; P=0.61 | No benefit over 24 weeks on measured social or cognitive outcomes |
| Le pilot, China | 41 ages 3 to 8; 24 IU every other day plus positive social interaction | ADOS-2 and SRS-2 improved versus placebo period | A positive combined-intervention pilot that needs independent parallel-group replication |
| Peng report, China | Reported n=45, but listed arms sum to 49; bilingual dose wording conflicts | Selective emotion-perception signal; anxiety and eye-reading null | Abstract-level signal too internally inconsistent for a clean estimate |
| TTA-121, Japan | 109 adult men; enhanced-bioavailability dose-ranging spray | Full-analysis primary comparisons null; per-protocol signal at 6 U/day | Product-specific exploratory dose work, not confirmation |
These studies used different formulations, schedules and outcomes. The Chinese pilot combined oxytocin with structured social interaction, while SOARS-B tested daily dosing over 24 weeks.
SOARS-B · 290 enrolled, primary outcome null
Phase 2 randomized placebo-controlled trial
Sikich L et al. New England Journal of Medicine. 2021
Among 290 randomized participants ages 3 to 17, 139 oxytocin and 138 placebo participants contributed post-baseline primary-outcome data. After 24 weeks, change on the modified ABC Social Withdrawal score differed by -0.2 points between groups (95% CI -1.5 to 1.0; P=0.61). Secondary social and cognitive outcomes generally did not differ, and adverse-event incidence and severity were similar.
- Participants / model
- 290 children and adolescents ages 3 to 17 with autism spectrum disorder
- Treatment
- Intranasal oxytocin, flexible titration to a target total of 48 IU/day, versus placebo
- Follow-up
- 24 weeks
- Study design
- Multisite, phase 2, randomized, placebo-controlled, parallel trial; modified intention-to-treat analysis
- Funding
- US National Institute of Child Health and Human Development
This large disorder-specific trial is more informative for daily autism treatment than single-dose laboratory tasks. It does not test every formulation or paired behavioral intervention.
Read the original sourceChina pilot · 41 children, paired social interaction
Pilot randomized crossover trial
Le J et al. Psychotherapy and Psychosomatics. 2022
In 41 autistic children ages 3 to 8, six weeks of every-other-day intranasal oxytocin followed by positive social interaction improved ADOS-2 and SRS-2 scores versus the placebo period, with reported P values below 0.001 for total scores. It also changed some secondary behavioral and eye-tracking measures. This was a small pilot crossover study of a combined drug-plus-interaction procedure.
- Participants / model
- 41 autistic children ages 3 to 8 in Chengdu, China; 38 boys and 3 girls in the published table
- Treatment
- 24 IU intranasal oxytocin every other day, followed by 30 minutes of positive social interaction, versus matched placebo period
- Follow-up
- Two six-week treatment periods separated by a two-week washout
- Study design
- Double-blind randomized crossover pilot
- Funding
- Chinese national and institutional grants listed in the paper
The paired social interaction, small sample, crossover design, and highly male sample limit generalization. This result has not displaced the larger parallel-trial null finding.
Read the original sourceGuangzhou report · selective signals, inconsistent denominator
Chinese-language randomized trial abstract
Peng R, Jing J, Wei C. Journal of Guangzhou Medical University. 2018;46(3):44-47
The abstract reports eight weeks of oxytocin or placebo in children ages 6 to 12. It reports improvement in ratings of ambiguous happy faces, but no significant improvement in state anxiety or the Reading the Mind in the Eyes task. The abstract says 45 participants yet reports groups of 24 and 25, which sum to 49, and its Chinese and English dose wording is not fully consistent.
- Participants / model
- Reported as 45 Chinese children ages 6 to 12 with autism spectrum disorder; arm counts are internally inconsistent
- Treatment
- Nasal oxytocin versus placebo for eight weeks; exact daily dose is ambiguous across the bilingual abstract
- Follow-up
- Eight weeks with assessment through week 12
- Study design
- Prospective randomized double-blind placebo-controlled study, published abstract
- Funding
- 2017 Guangdong Medical Science and Technology Research Fund, B2017011
The Chinese and English abstracts report inconsistent denominators and doses, preventing a clean effect estimate.
Read the original sourceTTA-121 Japan · product-specific primary analysis null
Randomized multicenter crossover trial
Yamasue H et al. Brain. 2022
Of 109 randomized adult men with high-functioning autism, 103 completed the trial. Across 3, 6, 10, and 20 U/day periods, the prespecified dose-response contrast was not significant in the full analysis set (P=0.182). At 6 U/day, the primary reciprocity score difference versus placebo was -0.5 (95% CI -1.1 to 0.1; P=0.118) in the full analysis set. A per-protocol signal and proposed inverted-U pattern remained exploratory, and no secondary clinical or behavioral outcome improved in the full analysis set.
- Participants / model
- 109 randomized adult men with high-functioning autism at seven Japanese university hospitals
- Treatment
- TTA-121 enhanced-bioavailability nasal spray at 3, 6, 10, or 20 U/day versus placebo
- Follow-up
- Four-week treatment periods in a two-period crossover design
- Study design
- Double-blind, placebo-controlled, multicenter crossover dose-ranging trial
- Funding
- Non-US government research support; formulation developed for the program
Rabbit-brain exposure was reported as 3.6 times Syntocinon, so these unit doses cannot be assumed equivalent to every spray. The full-analysis primary result was null; a per-protocol result was positive.
Read the original sourceDoes a nasal dose make people trust or bond more?
The original trust-game result came from a laboratory experiment in 58 men. A much larger registered replication and pooled analysis found no meaningful increase in trust-game behavior. Neither design tested love, relationship quality, consent, or durable bonding.
In 2005, men given 24 IU transferred 17% more money on average in a trust game than placebo participants. In 2026, a registered replication in 211 participants found no effect; pooling it with another large replication yielded 532 participants and placed the effect inside a minimal range.
Kosfeld 2005 · historical trust signal
Randomized double-blind laboratory experiment
Kosfeld M et al. Nature. 2005
In the trust experiment, 58 male investors received 24 IU intranasal oxytocin or placebo 50 minutes before repeated monetary-transfer decisions. Average transfer was 17% higher with oxytocin (P=0.029, one-sided), while a separate nonsocial risk experiment did not differ. This was a laboratory economic endpoint, not a relationship or psychiatric outcome.
- Participants / model
- 58 male investors in the trust experiment; a separate risk experiment included 61 men
- Treatment
- Single 24 IU dose of Syntocinon nasal spray versus matched placebo
- Follow-up
- Single laboratory session, testing 50 minutes after administration
- Study design
- Randomized double-blind placebo-controlled economic-game experiment
- Funding
- MacArthur Foundation, Cogito Foundation, Swiss National Science Foundation, and University of Zurich program support
The primary paper later published a figure correction for three omitted placebo observations, while stating the statistical tests had included them. Later larger registered replications are essential context.
Read the original sourceKroll 2026 · no meaningful trust effect
Registered replication with pooled equivalence analysis
Kroll CF et al. Cortex. 2026
The 211-person replication found no evidence that intranasal oxytocin increased trust-game behavior. Pooling it with a separate 321-person replication produced 532 participants; equivalence testing placed the effect within a minimal range considered too small to interest most feasible laboratory studies. Baseline trust and reward or punishment sensitivity did not rescue the result.
- Participants / model
- 211 participants in the registered replication; 532 in the pooled analysis
- Treatment
- Intranasal oxytocin versus placebo in a trust-game paradigm
- Follow-up
- Single-session laboratory experiments
- Study design
- Registered replication plus pooled equivalence testing
This measured money-transfer decisions in a laboratory trust game, not relationship quality or bonding.
Read the original sourceDid early oxytocin prevent PTSD after trauma?
The trial missed its primary clinician-rated PTSD outcome and found no overall benefit across follow-up. A more symptomatic subgroup improved in a secondary analysis, which needs confirmation in another trial.
The study randomized 120 distressed emergency-department patients, mostly after accidents. The intention-to-treat analysis included 53 oxytocin and 54 placebo participants. Treatment was 40 IU twice daily for eight days, started within 12 days after trauma, with CAPS assessments through six months. This was prevention soon after trauma, not treatment of established chronic PTSD.
PTSD prevention trial · primary and overall results null
Multicenter randomized double-blind trial
van Zuiden M et al. Biological Psychiatry. 2017
One hundred twenty emergency-department patients with moderate to severe acute distress were randomized, and 107 entered the intention-to-treat analysis. Forty IU twice daily for eight days, begun within 12 days after trauma, did not reduce clinician-rated CAPS scores at 1.5 months or across follow-up. A high-baseline-symptom subgroup signal was secondary and requires replication.
- Participants / model
- 120 adults after trauma, 85% accident victims; intention-to-treat n=107, 53 oxytocin and 54 placebo
- Treatment
- 40 IU intranasal oxytocin twice daily versus placebo
- Follow-up
- Eight treatment days; follow-up through six months
- Study design
- Multicenter randomized double-blind placebo-controlled prevention trial
- Funding
- Non-US government research support
This was early prevention in distressed emergency-department patients, not treatment of established chronic PTSD.
Read the original sourceDoes intranasal oxytocin improve libido, orgasm, or sexual dysfunction?
It is not a reliable libido or sexual-dysfunction treatment in the controlled data. One small healthy-couple experiment found selective orgasm and partner-interaction rating changes, while better-targeted studies in women found no oxytocin-specific benefit.
| Study | People and design | Result |
|---|---|---|
| Healthy couples | 29 heterosexual couples; 24 IU acute crossover | No change in drive, arousal, erection, or lubrication; small-to-moderate selective orgasm and post-orgasm ratings, more pronounced in men |
| Women with sexual dysfunction | 30 women; 22-week on-demand crossover | Primary FSFI rose 26% with oxytocin and 31% with placebo; no treatment, sequence, or interaction effect |
| Healthy women in a laboratory | 27 women; acute 24 IU crossover | No subjective or vaginal-photoplethysmography benefit |
Endogenous oxytocin changing during sexual response is an association, not proof that an intranasal product treats dysfunction. A single case report can generate a question, but it cannot establish response frequency or causality.
Couples experiment · small selective effects, no increase in sexual drive
Randomized placebo-controlled crossover experiment
Behnia B et al. Hormones and Behavior. 2014
In 29 healthy heterosexual couples, 24 IU intranasal oxytocin did not change sexual drive, arousal, erection, or lubrication. Models found small-to-moderate selective effects on orgasm or post-orgasm ratings and some partner-interaction measures, more pronounced in men. Biomarkers were unchanged.
- Participants / model
- 29 healthy heterosexual couples, 58 participants
- Treatment
- Single 24 IU intranasal oxytocin dose versus placebo in a naturalistic setting
- Follow-up
- Acute crossover sessions
- Study design
- Randomized placebo-controlled naturalistic crossover experiment
This small healthy-couple experiment did not test treatment of diagnosed sexual dysfunction and did not find a general arousal or libido effect.
Read the original sourceSexual dysfunction trial · placebo improved more on the primary scale
Randomized double-blind crossover trial
Muin DA et al. Fertility and Sterility. 2015
Thirty premenopausal and postmenopausal women with sexual dysfunction used 32 IU within 50 minutes before intercourse. Female Sexual Function Index scores increased 26% during oxytocin and 31% during placebo. There was no significant treatment, sequence, or interaction effect across the 22-week crossover trial.
- Participants / model
- 30 premenopausal and postmenopausal women with sexual dysfunction
- Treatment
- 32 IU intranasal oxytocin or placebo within 50 minutes before intercourse
- Follow-up
- Two eight-week treatment periods, two-week washout, 22 weeks total
- Study design
- Randomized prospective double-blind placebo-controlled crossover trial
Both periods improved, so before-after change cannot be credited to oxytocin.
Read the original sourceLaboratory crossover · subjective and physiologic outcomes null
Double-blind placebo-controlled crossover experiment
Kruger THC et al. Journal of Clinical Psychopharmacology. 2018
In 27 healthy women, a single 24 IU intranasal dose did not change sexual drive, arousal, orgasm-related subjective measures, vaginal photoplethysmography amplitude, or vaginal blood volume compared with placebo.
- Participants / model
- 27 healthy women; mean age 27.5 years
- Treatment
- Single 24 IU intranasal oxytocin dose versus placebo
- Follow-up
- Acute laboratory crossover sessions
- Study design
- Double-blind placebo-controlled crossover laboratory experiment
High internal control comes with limited real-world and clinical-dysfunction generalizability.
Read the original sourceDoes intranasal oxytocin reach the brain, and when does it act?
Human and animal studies support effects on brain activity after nasal administration. How much oxytocin reaches the brain depends on the formulation and delivery device; a plasma measurement alone does not establish brain exposure.
The Pitocin label gives a plasma half-life of about 1 to 6 minutes for injected oxytocin. That does not measure how long oxytocin remains in the brain after a nasal spray.
TTA-121 developers reported 3.6-fold higher rabbit-brain exposure than Syntocinon. Equal unit doses of those two formulations therefore did not produce equal brain exposure in rabbits.
Pitocin label · indications, route, monitoring, harms
Current US prescribing information
DailyMed, US National Library of Medicine, revised March 2026
The label identifies Pitocin as synthetic oxytocin 10 units/mL for intravenous infusion or intramuscular injection. It covers medically indicated initiation or improvement of uterine contractions, selected abortion management, third-stage uterine contraction, and control of postpartum bleeding or hemorrhage. It says the drug is not indicated for elective induction. Induction or stimulation requires intravenous infusion in a hospital with continuous observation and fetal monitoring.
- The label reports a plasma half-life of about 1 to 6 minutes.
- Excess exposure can cause uterine hypertonicity, tetanic contraction, rupture, fetal hypoxia, and death.
- Its antidiuretic action can cause severe water intoxication with convulsions or coma during prolonged high-dose infusion.
- Participants / model
- Pregnant and postpartum patients in monitored obstetric care
- Treatment
- Oxytocin injection, 10 units/mL; intravenous infusion for induction or stimulation and intravenous infusion or intramuscular injection in specified postpartum use
- Follow-up
- Acute, clinician-controlled obstetric administration
- Study design
- FDA-regulated product label
A product label defines approved use and warnings. It does not validate intranasal behavioral or sexual uses.
Read the original sourceMethods review · route, device, dose, timing, replication
Translational methods review
Quintana DS et al. Molecular Psychiatry. 2021
The review finds converging human and animal evidence that intranasal delivery can produce functionally relevant central effects, while emphasizing unresolved route mechanisms and the need to account for device, dose, timing, preregistration, statistical power, reproducibility, and sex. It does not support treating one CSF timing estimate as a universal nasal half-life.
- Participants / model
- Human and animal intranasal oxytocin literature
- Treatment
- Intranasal oxytocin across formulations, devices, and experimental protocols
- Follow-up
- Literature through 2020
- Study design
- Narrative translational methods review
A methods review supports interpretation of route and measurement. It is not proof of efficacy for any diagnosis.
Read the original sourceTTA-121 Japan · product-specific primary analysis null
Randomized multicenter crossover trial
Yamasue H et al. Brain. 2022
Of 109 randomized adult men with high-functioning autism, 103 completed the trial. Across 3, 6, 10, and 20 U/day periods, the prespecified dose-response contrast was not significant in the full analysis set (P=0.182). At 6 U/day, the primary reciprocity score difference versus placebo was -0.5 (95% CI -1.1 to 0.1; P=0.118) in the full analysis set. A per-protocol signal and proposed inverted-U pattern remained exploratory, and no secondary clinical or behavioral outcome improved in the full analysis set.
- Participants / model
- 109 randomized adult men with high-functioning autism at seven Japanese university hospitals
- Treatment
- TTA-121 enhanced-bioavailability nasal spray at 3, 6, 10, or 20 U/day versus placebo
- Follow-up
- Four-week treatment periods in a two-period crossover design
- Study design
- Double-blind, placebo-controlled, multicenter crossover dose-ranging trial
- Funding
- Non-US government research support; formulation developed for the program
Rabbit-brain exposure was reported as 3.6 times Syntocinon, so these unit doses cannot be assumed equivalent to every spray. The full-analysis primary result was null; a per-protocol result was positive.
Read the original sourceWhat is known about repeated intranasal safety?
Five autism trials involving 223 participants found no clear excess of the common adverse events assessed. That sample is too small to estimate rare harms, and it does not establish long-term daily safety or safety in pregnancy.
Across five trials and 223 autistic participants, nasal discomfort, irritability, tiredness, diarrhea, and skin irritation were reported, but none was statistically associated with treatment allocation. Severe events were sparse and occurred in both groups: aggression in two oxytocin and one placebo participant, and one seizure in each group.
- The meta-analysis cannot estimate very rare harms from 223 people.
- Trial-grade sprays and adverse-event monitoring do not automatically transfer to a compounded or research-market product.
- Obstetric injection warnings describe a different exposure and setting, but they are a reminder that this peptide has potent peripheral effects.
Safety meta-analysis · 223 participants, narrow evidence base
Systematic review and meta-analysis of randomized trials
Cai Q, Feng L, Yap KZ. Psychiatry and Clinical Neurosciences. 2018
Five autism trials contributed 223 participants, 123 oxytocin and 100 placebo. Common reported events included nasal discomfort 14.3%, irritability 9.0%, tiredness 7.2%, diarrhea 4.5%, and skin irritation 4.5%; none was statistically associated with allocation. Five severe events were reported: aggression in two oxytocin and one placebo participant, and seizures in one participant per group.
- Participants / model
- 223 autistic participants across five randomized trials
- Treatment
- Repeated intranasal oxytocin versus placebo for at least one month in the included trials
- Follow-up
- At least one month; studies published before January 1, 2017
- Study design
- Systematic review and pooled adverse-event analysis
Small trials and inconsistent adverse-event capture cannot rule out uncommon, delayed, pregnancy-related, or formulation-specific harms. Percentages are pooled occurrence, not proven drug-attributable incidence.
Read the original sourcePitocin label · indications, route, monitoring, harms
Current US prescribing information
DailyMed, US National Library of Medicine, revised March 2026
The label identifies Pitocin as synthetic oxytocin 10 units/mL for intravenous infusion or intramuscular injection. It covers medically indicated initiation or improvement of uterine contractions, selected abortion management, third-stage uterine contraction, and control of postpartum bleeding or hemorrhage. It says the drug is not indicated for elective induction. Induction or stimulation requires intravenous infusion in a hospital with continuous observation and fetal monitoring.
- The label reports a plasma half-life of about 1 to 6 minutes.
- Excess exposure can cause uterine hypertonicity, tetanic contraction, rupture, fetal hypoxia, and death.
- Its antidiuretic action can cause severe water intoxication with convulsions or coma during prolonged high-dose infusion.
- Participants / model
- Pregnant and postpartum patients in monitored obstetric care
- Treatment
- Oxytocin injection, 10 units/mL; intravenous infusion for induction or stimulation and intravenous infusion or intramuscular injection in specified postpartum use
- Follow-up
- Acute, clinician-controlled obstetric administration
- Study design
- FDA-regulated product label
A product label defines approved use and warnings. It does not validate intranasal behavioral or sexual uses.
Read the original sourceFDA compounding Q&A · what approval does not cover
Current FDA regulatory guidance page
US Food and Drug Administration, updated 2026
FDA states that compounded drugs are not FDA-approved and that the agency does not verify their safety, effectiveness, or quality before marketing. Compounding may meet an individual need, but facility, formulation, concentration, and device still matter.
- Participants / model
- US compounded human drugs
- Treatment
- General compounding framework
- Study design
- FDA public guidance
This source does not decide whether a particular prescription or preparation satisfies every applicable compounding rule.
Read the original sourceIs an intranasal oxytocin product FDA-approved in the United States?
Syntocinon nasal solution once had a US NDA, but its approval was withdrawn in 1997 after the holder stopped marketing it. The 2026 Orange Book lists it as discontinued. A compounded nasal preparation is not an FDA-approved replacement.
| Product | Record | Status and implication |
|---|---|---|
| Pitocin injection | Current DailyMed label; 10 units/mL | Approved prescription obstetric product with labeled routes and hospital controls |
| Syntocinon nasal solution | NDA 012285; 40 USP units/mL | Approval withdrawn effective September 8, 1997 after sponsor-requested commercial discontinuation |
| A pharmacy-compounded nasal spray | Preparation-specific prescription and pharmacy record | Not FDA-approved; FDA has not premarket-verified its safety, effectiveness, or quality |
The 1997 notice did not say Syntocinon was withdrawn for danger or ineffectiveness. A current compounded spray still needs its own concentration, ingredients, device, storage instructions and beyond-use date; the former approval does not cover it.
Pitocin label · indications, route, monitoring, harms
Current US prescribing information
DailyMed, US National Library of Medicine, revised March 2026
The label identifies Pitocin as synthetic oxytocin 10 units/mL for intravenous infusion or intramuscular injection. It covers medically indicated initiation or improvement of uterine contractions, selected abortion management, third-stage uterine contraction, and control of postpartum bleeding or hemorrhage. It says the drug is not indicated for elective induction. Induction or stimulation requires intravenous infusion in a hospital with continuous observation and fetal monitoring.
- The label reports a plasma half-life of about 1 to 6 minutes.
- Excess exposure can cause uterine hypertonicity, tetanic contraction, rupture, fetal hypoxia, and death.
- Its antidiuretic action can cause severe water intoxication with convulsions or coma during prolonged high-dose infusion.
- Participants / model
- Pregnant and postpartum patients in monitored obstetric care
- Treatment
- Oxytocin injection, 10 units/mL; intravenous infusion for induction or stimulation and intravenous infusion or intramuscular injection in specified postpartum use
- Follow-up
- Acute, clinician-controlled obstetric administration
- Study design
- FDA-regulated product label
A product label defines approved use and warnings. It does not validate intranasal behavioral or sexual uses.
Read the original sourceOrange Book 2026 · nasal product discontinued
Current FDA drug-product directory
US Food and Drug Administration, Approved Drug Products with Therapeutic Equivalence Evaluations, 46th edition, 2026
The 2026 discontinued-products list includes Syntocinon oxytocin nasal solution, 40 USP units/mL, NDA 012285. The same list separately identifies discontinued injectable oxytocin products. It does not show a currently marketed US nasal oxytocin approval.
- Participants / model
- US approved-drug product records
- Treatment
- Syntocinon nasal solution 40 USP units/mL
- Follow-up
- Directory status as published in 2026
- Study design
- FDA regulatory directory
Discontinued listing describes market status. The reason for withdrawal comes from the 1997 Federal Register notice.
Read the original sourceFederal Register 1997 · why the nasal approval ended
FDA Federal Register notice
US Food and Drug Administration. Federal Register. 1997;62:42575-42577
FDA listed NDA 12-285 Syntocinon oxytocin nasal solution nasal spray among applications whose holders said the products were no longer marketed and requested withdrawal. The withdrawal became effective September 8, 1997. The notice did not make a safety-or-effectiveness finding about this product.
- Participants / model
- US regulatory record
- Treatment
- Syntocinon oxytocin nasal solution nasal spray
- Follow-up
- Withdrawal effective September 8, 1997
- Study design
- Official administrative notice
Commercial withdrawal is not evidence that current compounded formulations match the former approved product.
Read the original sourceFDA compounding Q&A · what approval does not cover
Current FDA regulatory guidance page
US Food and Drug Administration, updated 2026
FDA states that compounded drugs are not FDA-approved and that the agency does not verify their safety, effectiveness, or quality before marketing. Compounding may meet an individual need, but facility, formulation, concentration, and device still matter.
- Participants / model
- US compounded human drugs
- Treatment
- General compounding framework
- Study design
- FDA public guidance
This source does not decide whether a particular prescription or preparation satisfies every applicable compounding rule.
Read the original sourceWhat did the 1955 Nobel Prize actually recognize?
Vincent du Vigneaud’s prize recognized broad work on biologically important sulfur compounds, especially the first synthesis of a polypeptide hormone. His Nobel lecture identifies that hormone as oxytocin.
The disulfide bond made oxytocin central to du Vigneaud’s sulfur research. His group’s work established the structure and chemical synthesis of a biologically active peptide hormone, a major milestone in peptide chemistry.
Nobel record · what the 1955 prize actually recognized
Official Nobel lecture and prize record
du Vigneaud V. Nobel Lecture. December 12, 1955
The Nobel citation recognized work on biochemically important sulfur compounds, especially the first synthesis of a polypeptide hormone. Du Vigneaud identified that hormone as oxytocin and described its uterine-contracting and milk-ejecting biology and the research path to synthesis.
- Participants / model
- Historical chemistry record
- Treatment
- Chemical synthesis of oxytocin
- Follow-up
- Nobel lecture delivered in 1955
- Study design
- Official historical primary document
The prize recognized work on sulfur compounds, especially the synthesis of a polypeptide hormone.
Read the original sourceFDA SRS · molecular identity
Official substance identity record
US Food and Drug Administration, Substance Registration System
FDA records oxytocin under UNII 1JQS135EYN as the cyclic nine-residue peptide CYIQNCPLG with a disulfide link between cysteines 1 and 6 and an amidated glycine terminus.
- Participants / model
- Not applicable
- Treatment
- Substance identity only
- Follow-up
- Not applicable
- Study design
- Regulatory molecular registry
Identity does not establish a clinical effect for any route or indication.
Read the original sourceWhy B tier?
Oxytocin has established obstetric uses, but the nasal-spray evidence for autism symptoms, trust and sexual function is inconsistent. Larger trials have often failed to reproduce the benefits suggested by smaller experiments.
- Approved use: standardized injections for specified obstetric indications, with monitoring during labor induction or stimulation.
- Nasal research: some small studies reported benefits, while larger autism and trust studies found no meaningful effect on their main outcomes.
- What would change confidence: independent replication with a fixed product, prespecified clinical endpoint, adequate power, representative population, and useful duration.
Pitocin label · indications, route, monitoring, harms
Current US prescribing information
DailyMed, US National Library of Medicine, revised March 2026
The label identifies Pitocin as synthetic oxytocin 10 units/mL for intravenous infusion or intramuscular injection. It covers medically indicated initiation or improvement of uterine contractions, selected abortion management, third-stage uterine contraction, and control of postpartum bleeding or hemorrhage. It says the drug is not indicated for elective induction. Induction or stimulation requires intravenous infusion in a hospital with continuous observation and fetal monitoring.
- The label reports a plasma half-life of about 1 to 6 minutes.
- Excess exposure can cause uterine hypertonicity, tetanic contraction, rupture, fetal hypoxia, and death.
- Its antidiuretic action can cause severe water intoxication with convulsions or coma during prolonged high-dose infusion.
- Participants / model
- Pregnant and postpartum patients in monitored obstetric care
- Treatment
- Oxytocin injection, 10 units/mL; intravenous infusion for induction or stimulation and intravenous infusion or intramuscular injection in specified postpartum use
- Follow-up
- Acute, clinician-controlled obstetric administration
- Study design
- FDA-regulated product label
A product label defines approved use and warnings. It does not validate intranasal behavioral or sexual uses.
Read the original sourceSOARS-B · 290 enrolled, primary outcome null
Phase 2 randomized placebo-controlled trial
Sikich L et al. New England Journal of Medicine. 2021
Among 290 randomized participants ages 3 to 17, 139 oxytocin and 138 placebo participants contributed post-baseline primary-outcome data. After 24 weeks, change on the modified ABC Social Withdrawal score differed by -0.2 points between groups (95% CI -1.5 to 1.0; P=0.61). Secondary social and cognitive outcomes generally did not differ, and adverse-event incidence and severity were similar.
- Participants / model
- 290 children and adolescents ages 3 to 17 with autism spectrum disorder
- Treatment
- Intranasal oxytocin, flexible titration to a target total of 48 IU/day, versus placebo
- Follow-up
- 24 weeks
- Study design
- Multisite, phase 2, randomized, placebo-controlled, parallel trial; modified intention-to-treat analysis
- Funding
- US National Institute of Child Health and Human Development
This large disorder-specific trial is more informative for daily autism treatment than single-dose laboratory tasks. It does not test every formulation or paired behavioral intervention.
Read the original sourceKroll 2026 · no meaningful trust effect
Registered replication with pooled equivalence analysis
Kroll CF et al. Cortex. 2026
The 211-person replication found no evidence that intranasal oxytocin increased trust-game behavior. Pooling it with a separate 321-person replication produced 532 participants; equivalence testing placed the effect within a minimal range considered too small to interest most feasible laboratory studies. Baseline trust and reward or punishment sensitivity did not rescue the result.
- Participants / model
- 211 participants in the registered replication; 532 in the pooled analysis
- Treatment
- Intranasal oxytocin versus placebo in a trust-game paradigm
- Follow-up
- Single-session laboratory experiments
- Study design
- Registered replication plus pooled equivalence testing
This measured money-transfer decisions in a laboratory trust game, not relationship quality or bonding.
Read the original sourceSexual dysfunction trial · placebo improved more on the primary scale
Randomized double-blind crossover trial
Muin DA et al. Fertility and Sterility. 2015
Thirty premenopausal and postmenopausal women with sexual dysfunction used 32 IU within 50 minutes before intercourse. Female Sexual Function Index scores increased 26% during oxytocin and 31% during placebo. There was no significant treatment, sequence, or interaction effect across the 22-week crossover trial.
- Participants / model
- 30 premenopausal and postmenopausal women with sexual dysfunction
- Treatment
- 32 IU intranasal oxytocin or placebo within 50 minutes before intercourse
- Follow-up
- Two eight-week treatment periods, two-week washout, 22 weeks total
- Study design
- Randomized prospective double-blind placebo-controlled crossover trial
Both periods improved, so before-after change cannot be credited to oxytocin.
Read the original sourceStudies and sources
Pitocin label · indications, route, monitoring, harms
Current US prescribing information
DailyMed, US National Library of Medicine, revised March 2026
The label identifies Pitocin as synthetic oxytocin 10 units/mL for intravenous infusion or intramuscular injection. It covers medically indicated initiation or improvement of uterine contractions, selected abortion management, third-stage uterine contraction, and control of postpartum bleeding or hemorrhage. It says the drug is not indicated for elective induction. Induction or stimulation requires intravenous infusion in a hospital with continuous observation and fetal monitoring.
- The label reports a plasma half-life of about 1 to 6 minutes.
- Excess exposure can cause uterine hypertonicity, tetanic contraction, rupture, fetal hypoxia, and death.
- Its antidiuretic action can cause severe water intoxication with convulsions or coma during prolonged high-dose infusion.
- Participants / model
- Pregnant and postpartum patients in monitored obstetric care
- Treatment
- Oxytocin injection, 10 units/mL; intravenous infusion for induction or stimulation and intravenous infusion or intramuscular injection in specified postpartum use
- Follow-up
- Acute, clinician-controlled obstetric administration
- Study design
- FDA-regulated product label
A product label defines approved use and warnings. It does not validate intranasal behavioral or sexual uses.
Read the original sourceFDA SRS · molecular identity
Official substance identity record
US Food and Drug Administration, Substance Registration System
FDA records oxytocin under UNII 1JQS135EYN as the cyclic nine-residue peptide CYIQNCPLG with a disulfide link between cysteines 1 and 6 and an amidated glycine terminus.
- Participants / model
- Not applicable
- Treatment
- Substance identity only
- Follow-up
- Not applicable
- Study design
- Regulatory molecular registry
Identity does not establish a clinical effect for any route or indication.
Read the original sourceOrange Book 2026 · nasal product discontinued
Current FDA drug-product directory
US Food and Drug Administration, Approved Drug Products with Therapeutic Equivalence Evaluations, 46th edition, 2026
The 2026 discontinued-products list includes Syntocinon oxytocin nasal solution, 40 USP units/mL, NDA 012285. The same list separately identifies discontinued injectable oxytocin products. It does not show a currently marketed US nasal oxytocin approval.
- Participants / model
- US approved-drug product records
- Treatment
- Syntocinon nasal solution 40 USP units/mL
- Follow-up
- Directory status as published in 2026
- Study design
- FDA regulatory directory
Discontinued listing describes market status. The reason for withdrawal comes from the 1997 Federal Register notice.
Read the original sourceFederal Register 1997 · why the nasal approval ended
FDA Federal Register notice
US Food and Drug Administration. Federal Register. 1997;62:42575-42577
FDA listed NDA 12-285 Syntocinon oxytocin nasal solution nasal spray among applications whose holders said the products were no longer marketed and requested withdrawal. The withdrawal became effective September 8, 1997. The notice did not make a safety-or-effectiveness finding about this product.
- Participants / model
- US regulatory record
- Treatment
- Syntocinon oxytocin nasal solution nasal spray
- Follow-up
- Withdrawal effective September 8, 1997
- Study design
- Official administrative notice
Commercial withdrawal is not evidence that current compounded formulations match the former approved product.
Read the original sourceFDA compounding Q&A · what approval does not cover
Current FDA regulatory guidance page
US Food and Drug Administration, updated 2026
FDA states that compounded drugs are not FDA-approved and that the agency does not verify their safety, effectiveness, or quality before marketing. Compounding may meet an individual need, but facility, formulation, concentration, and device still matter.
- Participants / model
- US compounded human drugs
- Treatment
- General compounding framework
- Study design
- FDA public guidance
This source does not decide whether a particular prescription or preparation satisfies every applicable compounding rule.
Read the original sourceSOARS-B · 290 enrolled, primary outcome null
Phase 2 randomized placebo-controlled trial
Sikich L et al. New England Journal of Medicine. 2021
Among 290 randomized participants ages 3 to 17, 139 oxytocin and 138 placebo participants contributed post-baseline primary-outcome data. After 24 weeks, change on the modified ABC Social Withdrawal score differed by -0.2 points between groups (95% CI -1.5 to 1.0; P=0.61). Secondary social and cognitive outcomes generally did not differ, and adverse-event incidence and severity were similar.
- Participants / model
- 290 children and adolescents ages 3 to 17 with autism spectrum disorder
- Treatment
- Intranasal oxytocin, flexible titration to a target total of 48 IU/day, versus placebo
- Follow-up
- 24 weeks
- Study design
- Multisite, phase 2, randomized, placebo-controlled, parallel trial; modified intention-to-treat analysis
- Funding
- US National Institute of Child Health and Human Development
This large disorder-specific trial is more informative for daily autism treatment than single-dose laboratory tasks. It does not test every formulation or paired behavioral intervention.
Read the original sourceChina pilot · 41 children, paired social interaction
Pilot randomized crossover trial
Le J et al. Psychotherapy and Psychosomatics. 2022
In 41 autistic children ages 3 to 8, six weeks of every-other-day intranasal oxytocin followed by positive social interaction improved ADOS-2 and SRS-2 scores versus the placebo period, with reported P values below 0.001 for total scores. It also changed some secondary behavioral and eye-tracking measures. This was a small pilot crossover study of a combined drug-plus-interaction procedure.
- Participants / model
- 41 autistic children ages 3 to 8 in Chengdu, China; 38 boys and 3 girls in the published table
- Treatment
- 24 IU intranasal oxytocin every other day, followed by 30 minutes of positive social interaction, versus matched placebo period
- Follow-up
- Two six-week treatment periods separated by a two-week washout
- Study design
- Double-blind randomized crossover pilot
- Funding
- Chinese national and institutional grants listed in the paper
The paired social interaction, small sample, crossover design, and highly male sample limit generalization. This result has not displaced the larger parallel-trial null finding.
Read the original sourceGuangzhou report · selective signals, inconsistent denominator
Chinese-language randomized trial abstract
Peng R, Jing J, Wei C. Journal of Guangzhou Medical University. 2018;46(3):44-47
The abstract reports eight weeks of oxytocin or placebo in children ages 6 to 12. It reports improvement in ratings of ambiguous happy faces, but no significant improvement in state anxiety or the Reading the Mind in the Eyes task. The abstract says 45 participants yet reports groups of 24 and 25, which sum to 49, and its Chinese and English dose wording is not fully consistent.
- Participants / model
- Reported as 45 Chinese children ages 6 to 12 with autism spectrum disorder; arm counts are internally inconsistent
- Treatment
- Nasal oxytocin versus placebo for eight weeks; exact daily dose is ambiguous across the bilingual abstract
- Follow-up
- Eight weeks with assessment through week 12
- Study design
- Prospective randomized double-blind placebo-controlled study, published abstract
- Funding
- 2017 Guangdong Medical Science and Technology Research Fund, B2017011
The Chinese and English abstracts report inconsistent denominators and doses, preventing a clean effect estimate.
Read the original sourceTTA-121 Japan · product-specific primary analysis null
Randomized multicenter crossover trial
Yamasue H et al. Brain. 2022
Of 109 randomized adult men with high-functioning autism, 103 completed the trial. Across 3, 6, 10, and 20 U/day periods, the prespecified dose-response contrast was not significant in the full analysis set (P=0.182). At 6 U/day, the primary reciprocity score difference versus placebo was -0.5 (95% CI -1.1 to 0.1; P=0.118) in the full analysis set. A per-protocol signal and proposed inverted-U pattern remained exploratory, and no secondary clinical or behavioral outcome improved in the full analysis set.
- Participants / model
- 109 randomized adult men with high-functioning autism at seven Japanese university hospitals
- Treatment
- TTA-121 enhanced-bioavailability nasal spray at 3, 6, 10, or 20 U/day versus placebo
- Follow-up
- Four-week treatment periods in a two-period crossover design
- Study design
- Double-blind, placebo-controlled, multicenter crossover dose-ranging trial
- Funding
- Non-US government research support; formulation developed for the program
Rabbit-brain exposure was reported as 3.6 times Syntocinon, so these unit doses cannot be assumed equivalent to every spray. The full-analysis primary result was null; a per-protocol result was positive.
Read the original sourceKosfeld 2005 · historical trust signal
Randomized double-blind laboratory experiment
Kosfeld M et al. Nature. 2005
In the trust experiment, 58 male investors received 24 IU intranasal oxytocin or placebo 50 minutes before repeated monetary-transfer decisions. Average transfer was 17% higher with oxytocin (P=0.029, one-sided), while a separate nonsocial risk experiment did not differ. This was a laboratory economic endpoint, not a relationship or psychiatric outcome.
- Participants / model
- 58 male investors in the trust experiment; a separate risk experiment included 61 men
- Treatment
- Single 24 IU dose of Syntocinon nasal spray versus matched placebo
- Follow-up
- Single laboratory session, testing 50 minutes after administration
- Study design
- Randomized double-blind placebo-controlled economic-game experiment
- Funding
- MacArthur Foundation, Cogito Foundation, Swiss National Science Foundation, and University of Zurich program support
The primary paper later published a figure correction for three omitted placebo observations, while stating the statistical tests had included them. Later larger registered replications are essential context.
Read the original sourceKroll 2026 · no meaningful trust effect
Registered replication with pooled equivalence analysis
Kroll CF et al. Cortex. 2026
The 211-person replication found no evidence that intranasal oxytocin increased trust-game behavior. Pooling it with a separate 321-person replication produced 532 participants; equivalence testing placed the effect within a minimal range considered too small to interest most feasible laboratory studies. Baseline trust and reward or punishment sensitivity did not rescue the result.
- Participants / model
- 211 participants in the registered replication; 532 in the pooled analysis
- Treatment
- Intranasal oxytocin versus placebo in a trust-game paradigm
- Follow-up
- Single-session laboratory experiments
- Study design
- Registered replication plus pooled equivalence testing
This measured money-transfer decisions in a laboratory trust game, not relationship quality or bonding.
Read the original sourceSocial anxiety trial · self-evaluation changed, overall outcome did not
Randomized double-blind adjunct trial
Guastella AJ et al. Psychoneuroendocrinology. 2009
Twenty-five people with primary social anxiety disorder received 24 IU intranasal oxytocin or placebo with exposure therapy. Oxytocin improved positive self-evaluations of appearance and speech during sessions, but did not improve the overall treatment outcome. Symptom severity, dysfunctional cognition, and life impairment fell similarly in both groups.
- Participants / model
- 25 participants with primary social anxiety disorder
- Treatment
- 24 IU intranasal oxytocin or placebo as an adjunct to exposure therapy
- Follow-up
- Exposure-treatment course; the abstract does not report a durable post-treatment drug effect
- Study design
- Randomized double-blind placebo-controlled adjunct trial
A situation-specific self-rating change is not the same outcome as remission, disability reduction, or durable anxiety treatment.
Read the original sourcePTSD prevention trial · primary and overall results null
Multicenter randomized double-blind trial
van Zuiden M et al. Biological Psychiatry. 2017
One hundred twenty emergency-department patients with moderate to severe acute distress were randomized, and 107 entered the intention-to-treat analysis. Forty IU twice daily for eight days, begun within 12 days after trauma, did not reduce clinician-rated CAPS scores at 1.5 months or across follow-up. A high-baseline-symptom subgroup signal was secondary and requires replication.
- Participants / model
- 120 adults after trauma, 85% accident victims; intention-to-treat n=107, 53 oxytocin and 54 placebo
- Treatment
- 40 IU intranasal oxytocin twice daily versus placebo
- Follow-up
- Eight treatment days; follow-up through six months
- Study design
- Multicenter randomized double-blind placebo-controlled prevention trial
- Funding
- Non-US government research support
This was early prevention in distressed emergency-department patients, not treatment of established chronic PTSD.
Read the original sourceCouples experiment · small selective effects, no increase in sexual drive
Randomized placebo-controlled crossover experiment
Behnia B et al. Hormones and Behavior. 2014
In 29 healthy heterosexual couples, 24 IU intranasal oxytocin did not change sexual drive, arousal, erection, or lubrication. Models found small-to-moderate selective effects on orgasm or post-orgasm ratings and some partner-interaction measures, more pronounced in men. Biomarkers were unchanged.
- Participants / model
- 29 healthy heterosexual couples, 58 participants
- Treatment
- Single 24 IU intranasal oxytocin dose versus placebo in a naturalistic setting
- Follow-up
- Acute crossover sessions
- Study design
- Randomized placebo-controlled naturalistic crossover experiment
This small healthy-couple experiment did not test treatment of diagnosed sexual dysfunction and did not find a general arousal or libido effect.
Read the original sourceSexual dysfunction trial · placebo improved more on the primary scale
Randomized double-blind crossover trial
Muin DA et al. Fertility and Sterility. 2015
Thirty premenopausal and postmenopausal women with sexual dysfunction used 32 IU within 50 minutes before intercourse. Female Sexual Function Index scores increased 26% during oxytocin and 31% during placebo. There was no significant treatment, sequence, or interaction effect across the 22-week crossover trial.
- Participants / model
- 30 premenopausal and postmenopausal women with sexual dysfunction
- Treatment
- 32 IU intranasal oxytocin or placebo within 50 minutes before intercourse
- Follow-up
- Two eight-week treatment periods, two-week washout, 22 weeks total
- Study design
- Randomized prospective double-blind placebo-controlled crossover trial
Both periods improved, so before-after change cannot be credited to oxytocin.
Read the original sourceLaboratory crossover · subjective and physiologic outcomes null
Double-blind placebo-controlled crossover experiment
Kruger THC et al. Journal of Clinical Psychopharmacology. 2018
In 27 healthy women, a single 24 IU intranasal dose did not change sexual drive, arousal, orgasm-related subjective measures, vaginal photoplethysmography amplitude, or vaginal blood volume compared with placebo.
- Participants / model
- 27 healthy women; mean age 27.5 years
- Treatment
- Single 24 IU intranasal oxytocin dose versus placebo
- Follow-up
- Acute laboratory crossover sessions
- Study design
- Double-blind placebo-controlled crossover laboratory experiment
High internal control comes with limited real-world and clinical-dysfunction generalizability.
Read the original sourceSafety meta-analysis · 223 participants, narrow evidence base
Systematic review and meta-analysis of randomized trials
Cai Q, Feng L, Yap KZ. Psychiatry and Clinical Neurosciences. 2018
Five autism trials contributed 223 participants, 123 oxytocin and 100 placebo. Common reported events included nasal discomfort 14.3%, irritability 9.0%, tiredness 7.2%, diarrhea 4.5%, and skin irritation 4.5%; none was statistically associated with allocation. Five severe events were reported: aggression in two oxytocin and one placebo participant, and seizures in one participant per group.
- Participants / model
- 223 autistic participants across five randomized trials
- Treatment
- Repeated intranasal oxytocin versus placebo for at least one month in the included trials
- Follow-up
- At least one month; studies published before January 1, 2017
- Study design
- Systematic review and pooled adverse-event analysis
Small trials and inconsistent adverse-event capture cannot rule out uncommon, delayed, pregnancy-related, or formulation-specific harms. Percentages are pooled occurrence, not proven drug-attributable incidence.
Read the original sourceMethods review · route, device, dose, timing, replication
Translational methods review
Quintana DS et al. Molecular Psychiatry. 2021
The review finds converging human and animal evidence that intranasal delivery can produce functionally relevant central effects, while emphasizing unresolved route mechanisms and the need to account for device, dose, timing, preregistration, statistical power, reproducibility, and sex. It does not support treating one CSF timing estimate as a universal nasal half-life.
- Participants / model
- Human and animal intranasal oxytocin literature
- Treatment
- Intranasal oxytocin across formulations, devices, and experimental protocols
- Follow-up
- Literature through 2020
- Study design
- Narrative translational methods review
A methods review supports interpretation of route and measurement. It is not proof of efficacy for any diagnosis.
Read the original sourceNobel record · what the 1955 prize actually recognized
Official Nobel lecture and prize record
du Vigneaud V. Nobel Lecture. December 12, 1955
The Nobel citation recognized work on biochemically important sulfur compounds, especially the first synthesis of a polypeptide hormone. Du Vigneaud identified that hormone as oxytocin and described its uterine-contracting and milk-ejecting biology and the research path to synthesis.
- Participants / model
- Historical chemistry record
- Treatment
- Chemical synthesis of oxytocin
- Follow-up
- Nobel lecture delivered in 1955
- Study design
- Official historical primary document
The prize recognized work on sulfur compounds, especially the synthesis of a polypeptide hormone.
Read the original sourceWhy is oxytocin in B tier?
B tier reflects established obstetric uses alongside inconsistent findings from nasal-spray research. Larger autism and trust studies found no meaningful benefit on their main outcomes, and long-term safety data for daily behavioral use remain limited.
Does oxytocin treat social anxiety disorder?
A small adjunct trial changed how participants rated their own performance during exposure sessions, but it did not improve the treatment’s overall symptom, cognition, or life-impairment outcomes.
Twenty-five participants received 24 IU or placebo alongside exposure therapy. Positive self-evaluations of appearance and speech improved more with oxytocin as sessions progressed. The broader clinical outcomes improved similarly in both groups.
Social anxiety trial · self-evaluation changed, overall outcome did not
Randomized double-blind adjunct trial
Guastella AJ et al. Psychoneuroendocrinology. 2009
Twenty-five people with primary social anxiety disorder received 24 IU intranasal oxytocin or placebo with exposure therapy. Oxytocin improved positive self-evaluations of appearance and speech during sessions, but did not improve the overall treatment outcome. Symptom severity, dysfunctional cognition, and life impairment fell similarly in both groups.
A situation-specific self-rating change is not the same outcome as remission, disability reduction, or durable anxiety treatment.
Read the original source